Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2016
Price : $35 *
At a glance
- Drugs Gefitinib (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms GEFTREM
- 11 Oct 2016 Results (n=26) presented at the 41st European Society for Medical Oncology Congress
- 08 Jun 2016 Status changed from recruiting to completed.
- 05 Feb 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.